Eli Lilly and Company Tops Forecast On Cost Cuts, Sales Fall Short
Wall Street Journal -- Eli Lilly & Co.'s third-quarter earnings rose 38% as the company rebounded from a year-earlier quarter hamstrung by $549.8 million of charges as revenue edged higher.